IROA Technologies and the University of Florida (UF) agreed to collaborate on the analysis and validation of clinical tissue for finding potential biomarkers of liver cancer and other liver diseases. The collaboration will leverage IROA’s patented technology, software, and expertise along with the UF’s Clinical and Translational Science Institute Biorepository, which contains a diverse collection of normal and diseased human tissues and may be used for IRB-approved research.

In addition, UF’s Southeast Center for Integrated Metabolomics (SECIM) will provide metabolic profiling using the IROA protocol as a foundation for exploring liver biochemical diversity and disease response. UF will also provide medical support and interpretation of results through an established expert liver disease and mass spectrometry advisory committee.

IROA initially partnered with UF in September 2013 to join in the establishment of the SECIM, which was awarded a five-year $9 million grant from the NIH. The SECIM is developing an integrated metabolomics service to provide high-quality data, user-friendly statistical analysis tools, training, and pilot funding to help users get the most out of a metabolomics study, according to officials at the center.

Previous articleX-Chem, Pfizer to Tackle Multiple Targets in New Collab
Next articleLight-Sensitive Retina Cells in Dish Created with Human Stem Cells